Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib dose-escalation with salvage 177Lu-DOTATATE PRRT in advanced GEP neuroendocrine tumors
NL-OMON54089Phase 1Recruiting
- Sponsor
- Moleculaire geneeskunde
- Start
- Mar 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib and lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Moleculaire geneeskunde. Primary endpoint: Maximum tolerated dose of olaparib in combination with PRRT. Started Mar 2022; status: recruiting.
02
Drugs
olapariblutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON54089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54089.